References
- Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
- Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007. 12. 369(9573):1641–1657.
- Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006 Jan;48(2):116–132.
- Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113–120.
- Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun;10(6):595–607.
- Koltun WA. Better together: improved care of the IBD patient using the multi-disciplinary IBD center. Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):491–493.
- Sands BE, Siegel CA. Crohn’s disease. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease pathophysiology, diagnosis, management. 10th ed. Vol. 2. chapter 115. Philadelphia (PA): Elsevier Saunders; 2015. p. 1990–2023.
- Osterman MT, Lichtenstein GR. Ulcerative colitis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease pathophysiology, diagnosis, management. 10th ed. Vol. 2. chapter 116. Philadelphia (PA): Elsevier Saunders; 2015. p. 2023–2061.
- Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
- Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–990.
- Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27.
- Axelrod DA, Hayward R. Nonrandomized interventional study designs (Quasi-Experimental Designs). In: Penson DF, Wei JT, editors. Clinical research methods for surgeons. New York (NY): Humana Press; 2006. p. 63–76.
- Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar;105(3):501–523.
- Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009 Feb;104(2):465–483.
- Kamat N, Ganesh Pai C, Surulivel Rajan M, et al. Cost of illness in inflammatory bowel disease. Dig Dis Sci. 2017;62(9):2318–2326.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370.
- Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996;67(3):588–597.
- Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897.
- Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996 Aug;91(8):1571–1578.
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
- Bregenzer N, Lange A, Fürst A, et al. Patient education in inflammatory bowel disease does not influence patients knowledge and long-term psychosocial well-being. Z Gastroenterol. 2005 Apr;43(4):367–371.
- Goodhand JR, Wahed M, Rampton DS. Management of stress in inflammatory bowel disease: a therapeutic option? Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):661–679.
- Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–2933.
- Červený P, Bortlík M, Kuběna A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13:1244–1249.
- Bhatt J, Patil S, Joshi A, et al. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J Gastroenterol. 2009 Jul-Aug;28(4):143–146.
- Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Mar;27(Suppl 1):9–14.
- Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):215–226.
- Plevinsky JM, Greenley RN, Fishman LN. Self-management in patients with inflammatory bowel disease: strategies, outcomes, and integration into clinical care. Clin Exp Gastroenterol. 2016;9:259–267.